STAT3 and hepatocellular carcinoma: Sorafenib inhibits the phosphorylation of STAT3 at Tyr705, thereby suppressing growth and inducing apoptosis in HCC,23 indicating that STAT3 contributes to the antitumor effects of sorafenib on HCC.